Prostate Cancer
Conditions
Keywords
stage IIB prostate cancer, stage IIA prostate cancer
Brief summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Bicalutamide and goserelin may fight prostate cancer by reducing the production of testosterone. It is not yet known if radiation therapy is more effective with or without bicalutamide and goserelin in treating prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without bicalutamide and goserelin in treating patients who have localized prostate cancer.
Detailed description
OBJECTIVES: * Compare the potential beneficial impact of radiotherapy with or without adjuvant bicalutamide and goserelin on the long-term outcome of patients with localized prostate cancer. * Compare the acute and late radiation-induced side effects of these regimens in these patients. * Compare the biochemical/clinical disease-free survival, overall survival, and time to local progression in patients treated with these regimens. * Compare the time to clinical biological failure or death in patients treated with these regimens. * Compare the quality of life of patients treated with these regimens. OUTLINE: This is a randomized, multicenter study. Patients are stratified according to tumor class (T1b-c vs T2a), initial prostate-specific antigen level (10 ng/mL vs 10-20 ng/mL vs greater than 20 ng/mL), Gleason score (2-6 vs 7-10) and participating center. Patients are randomized to 1 of 2 treatment arms. * Arm I: Patients undergo 3-dimensional conformal radiotherapy or intensity-modulated radiotherapy once daily 5 days a week for 7-7.5 weeks. * Arm II: Patients receive adjuvant oral bicalutamide once daily on days 1-30 and goserelin subcutaneously on days 8 and 98. Beginning on day 8, patients undergo radiotherapy as in arm I. Quality of life is assessed at baseline and then at months 6, 12, 24, and 36. Patients are followed every 6 months for 5 years and then annually thereafter. PROJECTED ACCRUAL: A total of 800 patients (400 per treatment arm) will be accrued for this study within 5 years.
Interventions
DRUGbicalutamide
DRUGgoserelin acetate
PROCEDUREadjuvant therapy
RADIATIONradiation therapy
Sponsors
European Organisation for Research and Treatment of Cancer - EORTC
Study design
Allocation
RANDOMIZED
Primary purpose
TREATMENT
Eligibility
Sex/Gender
MALE
Age
No minimum to 80 Years
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Histologically confirmed stage II prostate cancer * T1b-c, N0, M0 with prostate-specific antigen (PSA) at least 10 ng/mL and/or Gleason score at least 7 (UICC 1997 classification) OR * T2a, N0, M0 (UICC 1997 classification) * Serum PSA no greater than 50 ng/mL * No involvement of pelvic lymph nodes PATIENT CHARACTERISTICS: Age: * 80 and under Performance status: * WHO 0-2 Life expectancy: * Not specified Hematopoietic: * Not specified Hepatic: * Not specified Renal: * Not specified Other: * No other malignancy within the past 5 years except adequately treated basal cell skin cancer * No psychological, familial, sociological, or geographical condition that would preclude study participation PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * Not specified Endocrine therapy: * No prior hormonal therapy Radiotherapy: * No prior pelvic radiotherapy Surgery: * No prior radical prostatectomy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Biochemical and clinical disease-free survival as measured by Logrank prostate-specific antigen progression every 6 months until year 5, and annually thereafter | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical disease-free survival as measured by Logrank every 6 months until year 5, and annually thereafter | — |
| Overall survival as measured by Logrank every 6 months until year 5, and annually thereafter | — |
| Local control as measured by Gray scale every 6 months until year 5, and annually thereafter | — |
| Acute toxicity as measured by NCI-CTC v2.0 up to 1 month post radiotherapy | — |
| Late toxicity as measured by EORTC and RTOG every 6 months until year 5, and annually thereafter | — |
| Quality of life as measured by EORTC QLQ-C30 and EORTC PR-25 every 6 months until year 5, and annually thereafter | — |
Countries
Belgium, Cyprus, Czechia, France, Ireland, Italy, Luxembourg, Netherlands, Poland, Spain, United Kingdom
Outcome results
None listed